| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2134241 | Experimental Hematology | 2010 | 9 Pages |
Abstract
KIR activation and HLA expression density are critical determinants for the efficacy of rituximab treatment. An explanation for the failure of rituximab treatment may be the protection of the tumor cells from ADCC by inhibiting NK-cell function with their surface HLA.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Andrea Borgerding, Justin Hasenkamp, Michael Engelke, Nina Burkhart, Lorenz Trümper, Jürgen Wienands, Bertram Glass,